BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37307617)

  • 21. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
    Hatfield LA; Huskamp HA; Lamont EB
    J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
    Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
    J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
    Wu JJ; Huang JW; Hsu KH; Huang YH; Chen KC; Tseng JS; Yang TY; Chang GC
    Anticancer Drugs; 2022 Nov; 33(10):e842-e849. PubMed ID: 36206101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
    Chen H; Ma X; Liu J; Yang Y; He Y; Fang Y; Wang L; Fang J; Zhao J; Zhuo M
    Clin Transl Oncol; 2024 Jul; 26(7):1664-1673. PubMed ID: 38329610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
    Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
    Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
    Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
    Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
    Kim H; Choi E; Heo MH; Kim JY; Park KU
    Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
    Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
    JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
    Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
    He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
    Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.